The CLL-17 study, comparing continuous ibrutinib to time-limited therapies, showed overlapping efficacy. Its main impact wasn't declaring a winner, but affirming that oncologists can base treatment decisions on patient preference for continuous vs. fixed-duration therapy, knowing outcomes will be similar.

Regimens like acalabrutinib plus venetoclax allow clinicians to start one drug and add the second months later. This flexibility accommodates patients' personal schedules, such as planned travel, making treatment initiation easier and improving the patient experience without compromising the regimen's core structure.

A common assumption that older patients may prefer simpler, continuous medication regimens is often incorrect. Clinical experience shows that the vast majority of patients, regardless of age, are interested in a time-limited therapy option, provided it can be delivered conveniently without infusions.

Adding obinutuzumab to acalabrutinib/venetoclax (triplet therapy) deepens responses but led to higher death rates in trials, partly due to COVID-19. This makes it a high-risk, high-reward strategy that experts reserve for younger, healthier patients with high-risk disease who prioritize coming off therapy.

While not a substitute for randomized trials, indirect cross-trial comparisons serve a crucial clinical function. They provide data-driven talking points to help patients make informed decisions based on personal priorities, such as maximizing remission duration, when direct comparative evidence does not exist.

When patients first choose an indefinite BTK inhibitor over a time-limited venetoclax regimen, they reveal underlying preferences (e.g., avoiding IV infusions, scheduling) that likely persist and should guide second-line treatment selection with pirtobrutinib.

Despite a major trial using rituximab in its pirtobrutinib-venetoclax combination, experts note a strong clinical preference for obinutuzumab as the more effective anti-CD20 antibody in CLL. This suggests that in real-world practice, clinicians may substitute obinutuzumab, adapting the trial regimen for perceived superior efficacy.

Despite the appeal of stopping treatment, a key insight from clinical practice is that patients' most critical question remains which therapy offers the longest period of remission, often overriding factors like treatment duration and oral-only options.

While many CLL patients prefer fixed-duration therapy to avoid continuous medication, this preference is often overridden by practical logistics. The burden of increased monitoring and frequent clinic visits associated with fixed-duration regimens leads some patients to opt for continuous therapy instead.